Psyence Biomedical Ltd. Common Shares (PBM) - Total Liabilities
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has total liabilities worth $943.07K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Psyence Biomedical Ltd. Common Shares to see how much of total assets are deployed in long-term investments.
Psyence Biomedical Ltd. Common Shares - Total Liabilities Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Psyence Biomedical Ltd. Common Shares (PBM) total assets.
Psyence Biomedical Ltd. Common Shares Competitors by Total Liabilities
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Judges Scientific Plc
LSE:JDG
|
UK | GBX104.20 Million |
|
Infinity Mining Ltd
AU:IMI
|
Australia | AU$392.72K |
|
Empire Metals Limited
LSE:EEE
|
UK | GBX318.04K |
|
60 Degrees Pharmaceuticals, Inc. Common Stock
NASDAQ:SXTP
|
USA | $1.75 Million |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
UK | GBX705.00K |
|
Birddog Technology Ltd
AU:BDT
|
Australia | AU$2.15 Million |
|
Vertu Motors Plc
LSE:VTU
|
UK | GBX1.18 Billion |
|
Real Estate Credit Investments Limited
LSE:RECI
|
UK | GBX117.51 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Psyence Biomedical Ltd. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Psyence Biomedical Ltd. Common Shares balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Psyence Biomedical Ltd. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual total liabilities of Psyence Biomedical Ltd. Common Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $594.37K | -95.09% |
| 2024-03-31 | $12.10 Million | -15.18% |
| 2023-03-31 | $14.27 Million | -12.87% |
| 2022-03-31 | $16.38 Million | +16104.79% |
| 2021-03-31 | $101.08K | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more